5/04/05

```
 NEWS  13 MAR 22  REGISTRY/ZREGISTRY enhanced with experimental property tags
 NEWS  14 APR 04  EPFULL enhanced with additional patent information and new
                  fields
 NEWS  15 APR 04  EMBASE - Database reloaded and enhanced
 NEWS  16 APR 18  New CAS Information Use Policies available online
 NEWS  17 APR 25  Patent searching, including current-awareness alerts (SDIs),
                  based on application date in CA/CAplus and USPATFULL/USPAT2
                  may be affected by a change in filing date for U.S.
                  applications.
 NEWS  18 APR 28  Improved searching of U.S. Patent Classifications for
                  U.S. patent records in CA/CAplus

 NEWS EXPRESS  JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:06:25 ON 04 MAY 2005

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                0.63       0.63

FILE 'REGISTRY' ENTERED AT 16:08:00 ON 04 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

10691624
```

5/04/05

STRUCTURE FILE UPDATES: 3 MAY 2005 HIGHEST RN 849720-40-7
DICTIONARY FILE UPDATES: 3 MAY 2005 HIGHEST RN 849720-40-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10691624.str



chain nodes :
13 14 15 16 17 19 20 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-10 6-13 9-16 13-14 13-15 16-17 17-19 19-20 19-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
13-14 13-15 16-17 17-19 19-20 19-22
exact bonds :
1-10 6-13 9-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

10691624

5/04/05

isolated ring systems :
containing 1 : 7 :

G1:C,S

G2:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS
20:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 16:08:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 474 TO ITERATE

100.0% PROCESSED 474 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8174 TO 10786
PROJECTED ANSWERS: 1181 TO 2299

L2 50 SEA SSS SAM L1

10691624

5/04/05

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.86       1.49

FILE 'CAPLUS' ENTERED AT 16:09:11 ON 04 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 4 May 2005  VOL 142 ISS 19
FILE LAST UPDATED: 3 May 2005  (20050503/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l2
L3            7 L2

=> d abs  bib hitstr 1-7
```

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB The invention relates to 2,2'-disubstituted biphenyls in which the substituents are chains containing structures associated with amino acids, peptides and amides. The claims describe compds. 2,2'-(C6H4)2R1R2, where R1, R2 are NH2, alkyl- or arylamino, CO2H, CONH2, CO-peptide, peptide-NH, etc. The biphenyl derivs. have calpain inhibitory activity and can be used for the preventive or therapeutic treatment of a degenerative disease. Thus, 2,2'-(C6H4)2(CO-L-Phe-L-Val-OMe)2 was prepared via peptide coupling reactions and showed IC50 = 10 nM for inhibition of calpain.

AN 2004:1015995 CAPLUS

DN 141:424440

TI Preparation of peptide biphenyl derivatives as calpain inhibitors

IN Herradon Garcia, Bernardo; Benito Cano, Esperanza; Chana Lopez, Antonio; Mann Morales, Enrique; Montero Aguado, Ana

PA Consejo Superior de Investigaciones Cientificas, Spain

SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2

DT Patent

LA Spanish

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004101494	A1	20041125	WO 2004-ES70034	20040511
WO 2004101494	B1	20050106		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2219187	A1	20041116	ES 2003-1125	20030514
PRAI ES 2003-1125	A	20030514		

OS MARPAT 141:424440

IT **740818-12-6P 794589-71-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide biphenyl derivs. as calpain inhibitors)

RN 740818-12-6 CAPLUS

CN L-Leucinamide, N-[[2'-[[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-L-phenylalanyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 794589-71-2 CAPLUS

CN L-Valine, 1,1'-([1,1'-biphenyl]-2,2'-diyldicarbonyl)bis[L-phenylalanyl-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

GI



I

II



III

AB Title compds. I [R1 = alkyl, quinolinyl; R2 = alkyl, cyclopropyl; R3 = (un)substituted Ph, pyridyl (sic); A = C2H2n; n = 0-2; R4, R5, R6, R7 = H, halo, CF3, etc.] and their pharmaceutically acceptable salts were prepared For example, coupling of 1-(6-methoxypyridin-3-yl)propylamine and benzoic acid II, e.g., prepared from 2-aminobenzoic acid and 1-butanesulfonyl chloride, followed by chiral HPLC purification afforded claimed aminosulfonylcarboxamide III. In Kv1.5 potassium flow inhibition assays, 7-examples of compds. I exhibited IC50 values ranging from 0.2-10 μM, e.g., the IC50 value of aminosulfonylcarboxamide III was 10 μM. Compds. I are claimed useful for the treatment of atrial fibrillation and atrial flutter.

AN 2004:800760 CAPLUS

DN 141:314015

TI Preparation of 2-aminosulfonylcarboxamides and related compounds as Kv1.5 potassium channel blockers

IN Brendel, Joachim; Wirth, Klaus; Goegelein, Heinz; Allessie, Maurits; Blaauw, Y.

PA Aventis Pharma Deutschland GmbH, Germany

SO Ger. Offen., 25 pp.
CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 10312061	A1	20040930	DE 2003-10312061	20030318
WO 2004082716	A1	20040930	WO 2004-EP2246	20040305
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005038083	A1	20050217	US 2004-796894	20040309
PRAI DE 2003-10312061	A	20030318		
US 2003-492640P	P	20030805		

OS MARPAT 141:314015

IT **767334-96-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-aminosulfonylcarboxamides and related compds. as Kv1.5 potassium channel blockers)

RN 767334-96-3 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(3-pyridinyl)ethyl]-, compd. with N-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]methanesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 498577-53-0
CMF C30 H29 N3 O3



CM 2

CRN 115256-11-6
CMF C19 H27 N3 O5 S2



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB Wholly aromatic polymers with various helical structures were prepared through the combination of two axially dissym. bifunctional compds. The palladium-catalyzed condensation of (R)-2,2-diethoxy-6,6'-dibromo-1,1'-binaphthyl with (R)-1,1'-binaphthyl-2,2'-diamine and the reaction of (S)-2,2-diethoxy-6,6'-dibromo-1,1'-binaphthyl with (S)-1,1'-binaphthyl-2,2'-diamine produced helical polyamines, and the chiral conformation was confirmed by their CD spectra and large sp. rotations. The combination of (R)-2,2-diethoxy-6,6'-dibromo-1,1'-binaphthyl and (S)-1,1'-binaphthyl-2,2'-diamine afforded polyamines with a zigzag conformation. The condensation of (R)-2,2'-dimethylbiphenyl-6,6'-dicarbonyl chloride with (R)-2,2'-diamino-6,6'-dimethylbiphenyl and the reaction of (S)-2,2'-dimethylbiphenyl-6,6'-dicarbonyl chloride with (S)-2,2'-diamino-6,6'-dimethylbiphenyl predominantly yielded cyclic dimers and tetramers because of the steric proximity of the reactive groups of the propagating species. The exptl. results indicated that the structures of the obtained polymers depended on the combination of the chirality of the bifunctional atropisomeric compds. and the position of the functional groups on the aromatic rings.

AN 2004:751774 CAPLUS

DN 141:411332

TI Syntheses of helical polymers through the combination of axially dissymmetric segments

AU Temma, Tomohisa; Kobayashi, Motoyasu; Agata, Yuya; Yamane, Tomoya; Miura, Jun; Takeishi, Makoto

CS Department of Polymer Science and Engineering, Yamagata University Yonezawa, Yamagata, 992-8510, Japan

SO Journal of Polymer Science, Part A: Polymer Chemistry (2004), 42(18), 4607-4620
CODEN: JPACEC; ISSN: 0887-624X

PB John Wiley & Sons, Inc.

DT Journal

LA English

IT **793673-63-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(syntheses of chiral aromatic helical polymamines and polyamides through the combination of axially dissym. segments)

RN 793673-63-9 CAPLUS

CN Poly[imino[(1R)-6,6'-dimethyl[1,1'-biphenyl]-2,2'-diyl]iminocarbonyl[(1S)-6,6'-dimethyl[1,1'-biphenyl]-2,2'-diyl]carbonyl] (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB The corrected structural formula of compound 6 on page 449 is given.

AN 2004:665427 CAPLUS

DN 142:240696

TI Peptide-biphenyl hybrids as calpain inhibitors. [Erratum to document cited in CA141:191050]

AU Montero, Ana; Mann, Enrique; Chana, Antonio; Herradon, Bernardo

CS Instituto de Quimica Organica General, C.S.I.C., Madrid, E-28006, Spain

SO Chemistry & Biodiversity (2004), 1(7), 1109
CODEN: CBHIAM; ISSN: 1612-1872

PB Verlag Helvetica Chimica Acta AG

DT Journal

LA English

IT **740818-12-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of peptide-biphenyl hybrids as calpain inhibitors (Erratum))

RN 740818-12-6 CAPLUS

CN L-Leucinamide, N-[[2'-[[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-L-phenylalanyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB Calpain is a cysteine protease that is activated by Ca2+. The over-activation of calpain, which occurs on increasing Ca2+ concentration, causes a variety of diseases. This paper reports exptl. results on the inhibition of calpain I (μ-calpain) by peptide-biphenyl hybrids. We have found that some peptide-biphenyl hybrids, with aromatic amino acids in the peptide chains, inhibit calpain with IC50 values in the nanomolar range. Since the peptide-biphenyl hybrids reported in the present paper do not possess a reactive electrophilic functionality, we hypothesize that they interfere with the activation of calpain by Ca2+, and present exptl. and computational results on the binding of peptide-biphenyl hybrids to Ca2+.

AN 2004:337261 CAPLUS

DN 141:191050

TI Peptide-biphenyl hybrids as calpain inhibitors

AU Montero, Ana; Mann, Enrique; Chana, Antonio; Herradon, Bernardo

CS Instituto de Quimica Organica General, C.S.I.C., Madrid, E-28006, Spain

SO Chemistry & Biodiversity (2004), 1(3), 442-457
CODEN: CBHIAM; ISSN: 1612-1872

PB Verlag Helvetica Chimica Acta AG

DT Journal

LA English

IT **740818-12-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of peptide-biphenyl hybrids as calpain inhibitors)

RN 740818-12-6 CAPLUS

CN L-Leucinamide, N-[[2'-[[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-L-phenylalanyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AB Disclosed is a remedy and/or a preventive for a chronic disease which contains an endothelial differentiation gene 2 (EDG-2) antagonist. Because of binding to a subtype EDG-2 of lysophosphatidic acid (LPA) receptor, an EDG-2 antagonist is useful in treating and/or preventing chronic diseases (for example, chronic asthma, glomerular nephritis, obesity, diseases caused by the progress of arteriosclerosis, rheumatoid and atopic diseases) induced and made chronic by tissue cells the proliferation of which is accelerated by LPA mediated by EDG-2. The inhibitory effect of 3-[N-[[2-[2-[(pyridine-3-ylmethylamino)carbonyl]phenyl]phenyl]carbonyl]-N-[2-(2,5-dimethoxyphenyl)ethyl]amino]propanoic acid (I) hydrochloride on LPA-induced proliferation of human prostate stroma cell was examined Also, a tablet containing I 50 mg/tablet was formulated.

AN 2004:20536 CAPLUS
DN 140:65261
TI Remedy for chronic disease containing EDG-2 antagonists
IN Nakade, Shinji; Habashita, Hiromu; Seko, Takuya
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002530	A1	20040108	WO 2003-JP6679	20030528
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 2002-185542	A	20020626		

OS MARPAT 140:65261
IT 629638-00-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(remedy for chronic disease containing EDG-2 antagonists)
RN 629638-00-2 CAPLUS
CN β-Alanine, N-[[2'-[[[(3-chlorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
GI



I

AB The title compds. [I; A = C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene each optionally substituted by 1-3 C1-4 alkyl group(s); the ring Cycl = C3-15 carbocyclic or 3- to 13-membered heterocyclic ring containing 1-4 N, 1-2 O, and/or 1-2 S atom(s); R1 = C1-4 alkyl, halo, cyano, trihalomethyl, OR6, SR7, NR8R9, NO2, CO2R10, CONR11R12, NR13COR14, SO2NR15R16, NR17SO2R18, S(O)R19, SO2R20; R6-R20 = H, C1-4 alkyl; R2, R3 = C1-4 alkyl, C1-4 alkoxy, halo; R4, R5 = H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, R21O-C1-4 alkyl, R22R23N-C1-4 alkyl, etc.; or NR4R5 is combined together to represent 3- to 15-membered mono-, di-, or tricyclic heterocyclyl containing at least one N atom and optionally substituted by OR25; wherein R21, R22, R23, R25 = H, C1-4 alkyl, C2-6 acyl, trihaloacetyl; wherein m, n = an integer of 0-4; p = an integer of 0-5; when p, m, or n is ≥2, R1, R2, or R3 is same or different] or prodrugs or salts thereof are prepared These compds. engage in lysophosphatidic acid (LPA) receptor bonding, in particular EDG-2 and antagonism and hence are useful in the prevention and/or treatment of urol. diseases (symptoms associated with prostate-gland enlargement or neuropathic bladder, bone tumors of the spine, disk herniation, spinal canal stenosis, symptoms attributed to diabetes, lower urinary tract infections (e.g., obstruction of lower urinary tract), inflammation of lower urinary tract and polyuria), cancer-associated diseases (solid tumor, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leukemia and wet metastasis of cancer), proliferative diseases (diseases accompanied by abnormal angiogenesis, blocked artery and lung fibrosis), inflammation/immune diseases (psoriasis; nephropathy, hepatitis and pneumonia), diseases caused by secretion disorder (Sjogren's syndrome) or brain-associated diseases (brain block, cerebral hemorrhage and cerebral or peripheral nerve disorder). Thus, 3-[N-[2-(2-carboxyphenyl)phenyl]-N-[2-(2,5-dimethoxyphenyl)ethyl]amino]propanoic acid-bound to Wang resin (preparation given) was condensed with 4-chlorobenzylamine using 1-hydroxybenzotriazole monohydrate and N,N-diisopropylcarbodiimide in DMF at room temperature for 16 h, followed by treatment with a 9:1 mixture of CF3CO2H and H2O at room temperature for 1 h to give 3-[N-[2-[2-[(4-chlorobenzylamine)carbonyl]phenyl]carbonyl]-N-[2-(2,5-dimethoxyphenyl)ethyl]amino]propanoic acid (II). In an EDG-2 antagonism assay, II showed IC50 of 0.41 μmol/L for inhibiting the increase in cellular calcium ion-concentration in CHO cells over-expressing human EDG-2 gene.

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
A tablet and an ampule contg. II were prepd.

AN 2003:950976 CAPLUS
DN 140:16961
TI Preparation of N-(2'-carbamoyl-1,1'-biphenyl-2-ylcarbonyl)-β-alanine derivatives as lysophosphatidic acid receptor antagonists
IN Habashita, Hiromu; Terakado, Masahiko; Nakade, Shinji; Seko, Takuya
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 434 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003099765	A1	20031204	WO 2003-JP6678	20030528
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 2002-153592	A	20020528		

OS MARPAT 140:16961
IT 629629-94-3P 629630-34-8P 629630-63-3P
629630-67-7P 629630-90-6P 629631-17-0P
629631-22-7P 629631-24-9P 629631-34-1P
629631-46-5P 629631-73-8P 629632-09-3P
629632-29-7P 629632-45-7P 629633-02-9P
629633-21-2P 629633-48-3P 629633-63-2P
629634-04-4P 629634-60-2P 629634-73-7P
629634-79-3P 629634-94-2P 629635-07-0P
629635-09-2P 629635-73-0P 629636-00-6P
629636-04-0P 629636-65-3P 629636-75-5P
629637-65-6P 629637-88-3P 629638-00-2P
629638-30-8P 629638-35-3P 629638-44-4P
629638-59-1P 629638-73-9P 629639-11-8P
629639-21-0P 629639-26-5P 629639-42-5P
629639-57-2P 629639-65-2P 629641-26-5P
629641-53-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(2'-carbamoyl-1,1'-biphenyl-2-ylcarbonyl)-β-alanine derivs. as lysophosphatidic acid (LPA) receptor and G protein-coupled receptor EDG-2 antagonists)
RN 629629-94-3 CAPLUS
CN β-Alanine, N-[2-(2,3-dimethoxyphenyl)ethyl]-N-[[2'-[[(2-thienylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 629630-34-8 CAPLUS
CN β-Alanine, N-[[2'-[[[(4-methoxyphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)





RN 629630-63-3 CAPLUS
CN β-Alanine, N-[[2'-[[(2-hydroxyethyl)(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-[2-(4-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 629630-67-7 CAPLUS
CN β-Alanine, N-[2-(4-methylphenyl)ethyl]-N-[[2'-[[(3-pyridinylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 629630-90-6 CAPLUS
CN β-Alanine, N-[[2'-[[[(2-fluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-[2-(4-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 629631-17-0 CAPLUS
CN β-Alanine, N-[[2'-[[[(3,5-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-[2-(4-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 629631-22-7 CAPLUS
CN β-Alanine, N-[2-(4-methylphenyl)ethyl]-N-[[2'-[[(2-phenylethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 629631-24-9 CAPLUS
CN β-Alanine, N-[2-(3-methoxyphenyl)ethyl]-N-[[2'-[[(1,2,3,4-tetrahydro-1-naphthalenyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 629631-34-1 CAPLUS
CN β-Alanine, N-[[2'-[[ethyl(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-[2-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 629631-46-5 CAPLUS
CN β-Alanine, N-[[2'-[[[2-(4-fluorophenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-[2-(3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 629631-73-8 CAPLUS
CN β-Alanine, N-[[2'-[[(3-hydroxy-1-phenylpropyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)



RN 629632-09-3 CAPLUS
CN β-Alanine, N-[[2'-[[[(1S)-2-hydroxy-1-phenylethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 629632-29-7 CAPLUS
CN β-Alanine, N-{[2'-[[[(3-methoxyphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl}-N-(2-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 629632-45-7 CAPLUS
CN β-Alanine, N-{[2'-[[[(2,6-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl}-N-(2-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 629633-02-9 CAPLUS
CN β-Alanine, N-{2-(3,4-dimethoxyphenyl)ethyl}-N-[[2'-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-(9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 629634-04-4 CAPLUS
CN β-Alanine, N-[[2'-[[[(1S)-2-hydroxy-1-phenylethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 629634-60-2 CAPLUS
CN β-Alanine, N-{[2'-[[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl}-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 629633-21-2 CAPLUS
CN β-Alanine, N-[2-(3,4-dimethoxyphenyl)ethyl]-N-{[2'-[[(2-phenylethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl}- (9CI) (CA INDEX NAME)



RN 629633-48-3 CAPLUS
CN β-Alanine, N-[[2'-[[(2,3-dihydro-1H-inden-1-yl)amino]carbonyl]{1,1'-biphenyl]-2-yl]carbonyl]-N-[2-(2-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 629634-73-7 CAPLUS
CN β-Alanine, N-[[2'-[[[2-(dimethylamino)ethyl](phenylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 629634-79-3 CAPLUS
CN β-Alanine, N-[2-(4-methoxyphenyl)ethyl]-N-[[2'-[[(1-naphthalenylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 629634-94-2 CAPLUS
CN β-Alanine, N-[[2'-[[[(2-chlorophenyl)methyl]amino]carbonyl][1,1'-

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
biphenyl]-2-yl]carbonyl]-N-[2-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 629635-07-0 CAPLUS
CN β-Alanine, N-[2-(4-methoxyphenyl)ethyl]-N-[[2'-[[(2-phenylethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 629635-09-2 CAPLUS
CN β-Alanine, N-[2-[4-(aminosulfonyl)phenyl]ethyl]-N-[[2'-[[(2-hydroxyethyl)(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 629635-73-0 CAPLUS
CN β-Alanine, N-[2-(2,4-dichlorophenyl)ethyl]-N-[[2'-[[methyl[(6-methyl-2-pyridinyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 629636-00-6 CAPLUS
CN β-Alanine, N-[[2'-[[[(3,5-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-[2-(4-ethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 629636-04-0 CAPLUS
CN β-Alanine, N-[(4-fluorophenyl)methyl]-N-[[2'-[[(1,2,3,4-tetrahydro-1-naphthalenyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 629636-65-3 CAPLUS
CN β-Alanine, N-[[2'-[[[(2,5-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-[2-(2-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 629636-75-5 CAPLUS
CN β-Alanine, N-[2-(2-methylphenyl)ethyl]-N-[[2'-[[(2-thienylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 629637-65-6 CAPLUS
CN β-Alanine, N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-N-[[2'-[[(2-hydroxyethyl)(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 629637-88-3 CAPLUS
CN β-Alanine, N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-N-[[2'-[[ethyl(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 629638-00-2 CAPLUS
CN β-Alanine, N-[[2'-[[[(3-chlorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 629638-30-8 CAPLUS
CN β-Alanine, N-[2-(3,5-dimethoxyphenyl)ethyl]-N-[[2'-[[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)





RN 629638-35-3 CAPLUS
CN β-Alanine, N-[2-(3,5-dimethoxyphenyl)ethyl]-N-[[2'-[[[(1R)-2-hydroxy-1-phenylethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 629638-44-4 CAPLUS
CN β-Alanine, N-[2-(3,5-dimethoxyphenyl)ethyl]-N-[[2'-[[(2-thienylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)





RN 629638-59-1 CAPLUS
CN β-Alanine, N-[2-(2-ethoxyphenyl)ethyl]-N-[[2'-[[(1-phenylethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 629638-73-9 CAPLUS
CN β-Alanine, N-[2-(2-ethoxyphenyl)ethyl]-N-[[2'-[[[(3-fluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 629639-11-8 CAPLUS
CN β-Alanine, N-[2-(3-ethoxyphenyl)ethyl]-N-[[2'-[[[(2-fluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 629639-21-0 CAPLUS
CN β-Alanine, N-[2-(3-ethoxyphenyl)ethyl]-N-[[2'-[[[(1R)-1-(4-methylphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 629639-26-5 CAPLUS
CN β-Alanine, N-[[2'-[[[(3,5-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-[2-(3-ethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 629639-42-5 CAPLUS
CN β-Alanine, N-[[2'-[[[(2,5-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 629639-57-2 CAPLUS
CN β-Alanine, N-[[2'-[[[(2-methylphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 629639-65-2 CAPLUS
CN β-Alanine, N-[[2'-[[[(2-chlorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 629641-26-5 CAPLUS
CN β-Alanine, N-[[2'-[[[(4-fluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 629641-53-8 CAPLUS
CN β-Alanine, N-(2-phenylethyl)-N-[[2'-[[(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

5/04/05

=> FIL STNGUIDE
=>
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 51.23 | 52.72

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION
CA SUBSCRIBER PRICE | -5.11 | -5.11

FILE 'STNGUIDE' ENTERED AT 16:31:25 ON 04 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 29, 2005 (20050429/UP).

=> logoff y
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 0.66 | 53.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION
CA SUBSCRIBER PRICE | 0.00 | -5.11

STN INTERNATIONAL LOGOFF AT 16:38:10 ON 04 MAY 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced

```
 NEWS  9  MAR 03  MEDLINE file segment of TOXCENTER reloaded
 NEWS  10 MAR 22  KOREAPAT now updated monthly; patent information enhanced
 NEWS  11 MAR 22  Original IDE display format returns to REGISTRY/ZREGISTRY
 NEWS  12 MAR 22  PATDPASPC - New patent database available
 NEWS  13 MAR 22  REGISTRY/ZREGISTRY enhanced with experimental property tags
 NEWS  14 APR 04  EPFULL enhanced with additional patent information and new
                  fields
 NEWS  15 APR 04  EMBASE - Database reloaded and enhanced
 NEWS  16 APR 18  New CAS Information Use Policies available online
 NEWS  17 APR 25  Patent searching, including current-awareness alerts (SDIs),
                  based on application date in CA/CAplus and USPATFULL/USPAT2
                  may be affected by a change in filing date for U.S.
                  applications.
 NEWS  18 APR 28  Improved searching of U.S. Patent Classifications for
                  U.S. patent records in CA/CAplus

 NEWS EXPRESS  JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:46:49 ON 04 MAY 2005

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 18:47:02 ON 04 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    3 MAY 2005  HIGHEST RN 849720-40-7
DICTIONARY FILE UPDATES:   3 MAY 2005  HIGHEST RN 849720-40-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.
```

5/04/05

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10691624.str



chain nodes :
13 14 15 16 17 19 20 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-10 6-13 9-16 13-14 13-15 16-17 17-19 19-20 19-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
13-14 13-15 16-17 17-19 19-20 19-22
exact bonds :
1-10 6-13 9-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

5/04/05

G1:C,S

G2:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 19:CLASS
20:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,S
G2 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 18:47:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 293 TO ITERATE

100.0% PROCESSED 293 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4833 TO 6887

5/04/05

PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 18:47:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6079 TO ITERATE

100.0% PROCESSED 6079 ITERATIONS 51 ANSWERS
SEARCH TIME: 00.00.01

L3 51 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 161.33 161.54

FILE 'CAPLUS' ENTERED AT 18:47:53 ON 04 MAY 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 May 2005 VOL 142 ISS 19
FILE LAST UPDATED: 3 May 2005 (20050503/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 10 L3

=> d abs bib hitstr 1-10

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
GI



I

AB The invention discloses the combination of one or more β-blockers and one or more Kv1.5 blockers, in particular phenylcarboxamides, and/or physiol. tolerable salts thereof, and the use of the combination for the treatment or prophylaxis of atrial arrhythmias. Preparation of e.g. I is described.

AN 2005:220139 CAPLUS
DN 142:274017
TI Combination of phenylcarboxylic acid amides with β-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias
IN Wirth, Klaus; Brendel, Joachim; Goegelein, Heinz
PA Aventis Pharma Deutschland GmbH, Germany
SO U.S. Pat. Appl. Publ., 14 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005054673	A1	20050310	US 2004-932431	20040901
DE 10341233	A1	20050324	DE 2003-10341233	20030908
WO 2005025674	A1	20050324	WO 2004-EP9837	20040903

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI DE 2003-10341233 A 20030908
US 2004-537612P P 20040120
IT **498577-46-1P 498577-53-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
GI



I

II



III

AB Title compds. I [R1 = alkyl, quinolinyl; R2 = alkyl, cyclopropyl; R3 = (un)substituted Ph, pyridyl (sic); A = C2H2n; n = 0-2; R4, R5, R6, R7 = H, halo, CF3, etc.] and their pharmaceutically acceptable salts were prepared For example, coupling of 1-(6-methoxypyridin-3-yl)propylamine and benzoic acid II, e.g., prepared from 2-aminobenzoic acid and 1-butanesulfonyl chloride, followed by chiral HPLC purification afforded claimed aminosulfonylcarboxamide III. In Kv1.5 potassium flow inhibition assays, 7-examples of compds. I exhibited IC50 values ranging from 0.2-10 μM, e.g., the IC50 value of aminosulfonylcarboxamide III was 10 μM. Compds. I are claimed useful for the treatment of atrial fibrillation and atrial flutter.

AN 2004:800760 CAPLUS
DN 141:314015
TI Preparation of 2-aminosulfonylcarboxamides and related compounds as Kv1.5 potassium channel blockers
IN Brendel, Joachim; Wirth, Klaus; Goegelein, Heinz; Allessie, Maurits; Blaauw, Y.
PA Aventis Pharma Deutschland GmbH, Germany
SO Ger. Offen., 25 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 10312061	A1	20040930	DE 2003-10312061	20030318
WO 2004082716	A1	20040930	WO 2004-EP2246	20040305

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(phenylcarboxylic acid amide combination with β-adrenoreceptor blocker for treatment of atrial arrhythmia)

RN 498577-46-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498577-53-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005038083 A1 20050217 US 2004-796894 20040309
PRAI DE 2003-10312061 A 20030318
US 2003-492640P P 20030805
OS MARPAT 141:314015
IT **498577-46-1P 498577-53-0P 767334-95-2P 767334-96-3P 767334-97-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-aminosulfonylcarboxamides and related compds. as Kv1.5 potassium channel blockers)

RN 498577-46-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498577-53-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 767334-95-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
N-[2-(3-pyridinyl)ethyl]-, compd. with N-[4-[4-(ethylheptylamino)-1-hydroxybutyl]phenyl]methanesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 498577-53-0
CMF C30 H29 N3 O3



CM 2

CRN 122647-31-8
CMF C20 H36 N2 O3 S



RN 767334-96-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(3-pyridinyl)ethyl]-, compd. with N-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]methanesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 498577-53-0
CMF C30 H29 N3 O3



L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CM 2

CRN 115256-11-6
CMF C19 H27 N3 O5 S2



RN 767334-97-4. CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(3-pyridinyl)ethyl]-, compd. with (2-butyl-3-benzofuranyl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 498577-53-0
CMF C30 H29 N3 O3



CM 2

CRN 1951-25-3
CMF C25 H29 I2 N O3



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

AB Background: The Kv1.5 channel, underlying IKur, is supposed to be atrial selective in pigs and humans. We investigated the effects of different potassium channel blockers, i.e. the IKur blockers AVE 0118; S9947 and S20951, with amiodarone (AM), dofetilide (DO), azimilide (AZ), ibutilide (IB), the IKs blocker HMR 1556, atropine (ATR), flecainide (FL), propafenone (PR), d,l-sotalol (SO), atenolol (ATE), and esmolol (ES), on the left and right atrial and ventricular refractoriness and left atrial vulnerability (LAV) in vivo in pigs. Material/Methods: In pentobarbital-anesthetized pigs (n=81), atrial and ventricular effective refractory periods (ERPs) were measured with the S1-S2-extrastimulus-method and QTc time from electrocardiograms. LAV was assessed after S2-extrastimulus to the left atrium. Results: All IKur blockers prolonged left stronger than right atrial ERP and did not change QTc. All IKr blockers predominantly prolonged the right vs. left atria. AM prolonged both atria equally, and ATR the left only. Pure beta blockers acted predominantly on the left atrium, as did FL and PR, while d,l-sotalol acted predominantly on the right. AVE 0118, S9947, S20951, ibutilide, and d,l-sotalol significantly decreased LAV (-100%, -100%, -82%, -53%, -42%; p<0.05), in contrast to all other drugs. Conclusions: The IKur blockers exhibited stronger effects on the left atrium, which itself has shorter refractoriness, but strikingly with no effect on ventricular repolarization, while IKr blockers, IKs blockers, and d,l-sotalol exerted predominantly right atrial effects and known ventricular effects. IKur blockers inhibited atrial tachyarrhythmias stronger than all available drugs. Therefore, IKur blockers seem to be promising new atrial-selective antiarrhythmic drugs.
AN 2004:703664 CAPLUS
DN 142:86448
TI Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs
AU Knobloch, Karsten; Brendel, Joachim; Rosenstein, Bjoern; Bleich, Markus; Busch, Andreas E.; Wirth, Klaus J.
CS DG Cardiovascular Diseases, Aventis Pharma, Frankfurtam Main, Germany
SO Medical Science Monitor (2004), 10(7), BR221-BR228
CODEN: MSMOFR; ISSN: 1234-1010
PB International Scientific Literature, Inc.
DT Journal
LA English
IT **498577-46-1**, S 20951
RL: PAC (Pharmacological activity); BIOL (Biological study)
(Ikur blocker S20951 prolonged left and right atrial ERP significantly with no effect on QT interval in pentobarbital-anesthetized pig)
RN 498577-46-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
GI



I

AB Title compds. [I; R1 = CO2R9, SO2R10, COR11, CONR12R13, CSNR12R13; R9, R10, R11, R12 = CmH2mR14; m = 0-4; R14 = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; m ≠ 0 if R14 = (cyclo)alkoxy, SO2Me, or OPh; R2 and R13 = independently H, alkyl, or CF3; R3 = CnH2nR16 or CHR18R19; n = 0-4; n ≠ 0 if R16 = OR17, SO2Me; R17 = H, (cyclo)alkyl, (un)substituted Ph, or pyridyl, R16 = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; R18 = H or CpH2pR16; p = 0-3; R19 = CO2H, CONH2, CH2OH, etc.; R4 = H, alkyl, or CF3; or NR3R4 = heterocyclyl; R5, R6, R7, R8 = independently H, halo, CF3, NO2, cyano, etc.; R30 and R31 = independently H or alkyl; CR30R31 = cyclopropyl; and pharmaceutically acceptable salts thereof] were prepared Thus, 2'-aminomethylbiphenyl-2-(N-phenethyl)carboxamide (preparation given) and NaHCO3 in dioxane and H2O were treated dropwise with 4-trifluoromethylbenzyl-N-succinimide carbonate (preparation given) in dioxane followed by 12 h stirring at room temperature to give 2'-(4-trifluoromethylbenzyloxycarbonylaminomethyl)-biphenyl-2-(N-phenethyl)carboxamide. Tested I inhibited Kv1.5 potassium flow with IC50 = 0.2 μM - 11.3 μM. Thus, I are especially suitable as antiarrhythmic active agents, in particular for the treatment and prophylaxis of atrial arrhythmia, e.g. atrial fibrillation (AF) or atrial flutter (no data).

AN 2003:196948 CAPLUS
DN 138:221357
TI Preparation of 2'-aminomethylbiphenyl-2-carboxamides as Kv1.5 potassium channel blockers
IN Brendel, Joachim; Schmidt, Wolfgang; Below, Peter
PA Aventis Pharma Deutschland GmbH, Germany
SO U.S., 65 pp., Cont.-in-part of U.S. Ser. No. 675,674.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6531495	B1	20030311	US 2000-698078	20001030

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

	DE 19947457	A1	20010405	DE 1999-19947457	19991002
	US 2003171351	A1	20030911	US 2002-252385	20020924
	US 6686395	B2	20040203		
	US 2004102513	A1	20040527	US 2003-691624	20031024
PRAI	DE 1999-19947457	A	19991002		
	US 2000-675674	A2	20000929		
	US 2000-698078	A3	20001030		
	US 2002-252385	A3	20020924		

OS MARPAT 138:221357
IT 332378-64-0P 332378-68-4P 498577-45-0P
498577-46-1P 498577-48-3P 498577-49-4P
498577-50-7P 498577-51-8P 498577-52-9P
498577-53-0P 498577-54-1P 498577-55-2P
498577-56-3P 498577-61-0P 498578-40-8P
498578-44-2P 498578-45-3P 498578-46-4P
498578-47-5P 498578-48-6P 498578-49-7P
498578-62-4P 498578-63-5P 498578-65-7P
498578-66-8P 498578-68-0P 498578-70-4P
498578-71-5P 498578-72-6P 498578-74-8P
498578-76-0P 498578-77-1P 498578-92-0P
498578-95-3P 498578-96-4P 498578-98-6P
498578-99-7P 498579-00-3P 498579-01-4P
498579-07-0P 498579-15-0P 498579-18-3P
498579-43-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiarrhythmic; preparation of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)

RN 332378-64-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(3-methylbutyl)-2'-[[[(1-methylethyl)sulfonyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 332378-68-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(1-methylethyl)sulfonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 498577-45-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(phenylmethyl)sulfonyl]amino]methyl]-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 498577-46-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498577-48-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 498577-49-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)





RN 498577-50-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)





RN 498577-51-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(4-methoxyphenyl)-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 498577-55-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[3-(4-ethoxyphenyl)-1-oxopropyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 498577-56-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[(1-oxo-3-phenylbutyl)amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 498577-61-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(1-oxido-3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 498578-40-8 CAPLUS

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 498577-52-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(4-methoxyphenyl)-2'-[[(1-oxo-3-phenylpropyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 498577-53-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 498577-54-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN [1,1'-Biphenyl]-2-carboxamide, N-[(1S)-3-methyl-1-[[(2,2,2-trifluoroethyl)amino]carbonyl]butyl]-2'-[[(1-oxo-3-phenylpropyl)amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-44-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[3-(2-methylphenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498578-45-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[3-(4-fluorophenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 498578-46-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[3-(4-methylphenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-47-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[3-(4-hydroxyphenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-62-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(cyclopropylmethyl)-2'-[[(4-methyl-1-oxopentyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-63-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(cyclopropylmethyl)-2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-65-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(3-methylbutyl)-2'-[[(phenoxyacetyl)amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 498578-48-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[3-(4-methoxyphenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-49-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[3-(3,4-difluorophenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 498578-66-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(3-methylbutyl)-2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-68-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[(4-methyl-1-oxopentyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-70-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 498578-71-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[(3-methyl-1-oxopentyl)amino]methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 498578-72-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-74-8 CAPLUS

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-76-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(6-methyl-2-pyridinyl)methyl]-2'-[[[(3R)-3-(4-nitrophenyl)-1-oxobutyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-77-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(4-fluorophenyl)-2'-[[[(4-fluorophenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 498578-92-0 CAPLUS
CN 2-Pyrimidinepropanamide, N-[[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]- (9CI) (CA INDEX NAME)





RN 498578-95-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[(4-fluorophenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 498578-96-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(6-methyl-2-pyridinyl)methyl]-2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-98-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[(4-hydroxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 498578-99-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-6,6'-dimethyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 498579-00-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[3-(1-methylethoxy)propyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
N-[[4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)





RN 498579-43-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 498579-01-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-cyclopentyl-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498579-07-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(1,3-dimethylbutyl)-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498579-15-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(1H-benzimidazol-2-ylmethyl)-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498579-18-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
GI



I

AB Title compds. [I; R1 = CO2R9, SO2R10, COR11, CONR12R13, CSNR12R13; R9, R10, R11, R12 = CmH2mR14; m = 0-4; R14 = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; m ≠ 0 if R14 = (cyclo)alkoxy, SO2Me, or OPh; R2 and R13 = independently H, alkyl, or CF3; R3 = CnH2nR16 or CHR18R19; n = 0-4; n ≠ 0 if R16 = OR17, SO2Me; R17 = H, (cyclo)alkyl, (un)substituted Ph, or pyridyl, R16 = (fluoro)alkyl, cycloalkyl, (un)substituted Ph, naphthyl, furyl, etc.; R18 = H or CpH2pR16; p = 0-3; R19 = CO2H, CONH2, CH2OH, etc.; R4 = H, alkyl, or CF3; or NR3R4 = heterocyclyl; R5, R6, R7, R8 = independently H, halo, CF3, NO2, cyano, etc.; R30 and R31 = independently H or alkyl; CR30R31 = cyclopropyl; and pharmaceutically acceptable salts thereof] were prepared Thus, 2'-aminomethylbiphenyl-2-(N-phenethyl)carboxamide (preparation given) and NaHCO3 in dioxane and H2O were treated dropwise with 4-trifluoromethylbenzyl-N-succinimide carbonate (preparation given) in dioxane followed by 12 h stirring at room temperature to give 2'-(4-trifluoromethylbenzyloxycarbonylaminomethyl)-biphenyl-2-(N-phenethyl)carboxamide. Tested I inhibited Kv1.5 potassium flow with IC50 = 0.2 μM - 11.3 μM. Thus, I are especially suitable as antiarrhythmic active agents, in particular for the treatment and prophylaxis of atrial arrhythmia, e.g. atrial fibrillation (AF) or atrial flutter (no data).
AN 2003:193044 CAPLUS
DN 138:167521
TI Preparation of 2'-aminomethylbiphenyl-2-carboxamides as Kv1.5 potassium channel blockers.
IN Brendel, Joachim; Schmidt, Wolfgang; Below, Peter
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001025189	A1	20010412	WO 2000-EP9151	20000919
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,				

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 19947457	A1	20010405	DE 1999-19947457		19991002
CA 2385859	AA	20010412	CA 2000-2385859		20000919
BR 2000014465	A	20020611	BR 2000-14465		20000919
EP 1222163	A1	20020717	EP 2000-967703		20000919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
JP 2003511363	T2	20030325	JP 2001-528137		20000919
EE 200200160	A	20030415	EE 2002-160		20000919
AU 766365	B2	20031016	AU 2000-77778		20000919
NZ 518065	A	20040827	NZ 2000-518065		20000919
NO 2002001398	A	20020531	NO 2002-1398		20020320
PRAI DE 1999-19947457	A	19991002			
WO 2000-EP9151	W	20000919			

OS MARPAT 138:187521

IT 332378-64-0P 332378-68-4P 498577-45-0P
498577-46-1P 498577-48-3P 498577-49-4P
498577-50-7P 498577-51-8P 498577-52-9P
498577-53-0P 498577-54-1P 498577-55-2P
498577-56-3P 498577-61-0P 498578-40-8P
498578-44-2P 498578-45-3P 498578-46-4P
498578-47-5P 498578-48-6P 498578-49-7P
498578-62-4P 498578-63-5P 498578-65-7P
498578-66-8P 498578-68-0P 498578-70-4P
498578-71-5P 498578-72-6P 498578-74-8P
498578-76-0P 498578-77-1P 498578-92-0P
498578-95-3P 498578-96-4P 498578-98-6P
498578-99-7P 498579-00-3P 498579-01-4P
498579-07-0P 498579-15-0P 498579-18-3P
498579-43-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiarrhythmic; preparation of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)

RN 332378-64-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(3-methylbutyl)-2'-[[[(1-methylethyl)sulfonyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 332378-68-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(1-methylethyl)sulfonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 498577-45-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(phenylmethyl)sulfonyl]amino]methyl]-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 498577-46-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 498577-48-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 498577-49-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)





RN 498577-50-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 498577-51-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(4-methoxyphenyl)-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498577-52-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(4-methoxyphenyl)-2'-[[(1-oxo-3-phenylpropyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 498577-53-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 498577-54-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 498577-55-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[3-(4-ethoxyphenyl)-1-oxopropyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 498577-56-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[(1-oxo-3-phenylbutyl)amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 498577-61-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[2-(1-oxido-3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 498578-40-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(1S)-3-methyl-1-[[(2,2,2-trifluoroethyl)amino]carbonyl]butyl]-2'-[[(1-oxo-3-phenylpropyl)amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-44-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[3-(2-methylphenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 498578-45-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[3-(4-fluorophenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498578-46-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[3-(4-methylphenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 498578-47-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[3-(4-hydroxyphenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498578-48-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[3-(4-methoxyphenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 498578-49-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[3-(3,4-difluorophenyl)-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-62-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(cyclopropylmethyl)-2'-[[(4-methyl-1-oxopentyl)amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 498578-68-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[(4-methyl-1-oxopentyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-70-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-71-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[(3-methyl-1-oxopentyl)amino]methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 498578-63-5 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(cyclopropylmethyl)-2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-65-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(3-methylbutyl)-2'-[[(phenoxyacetyl)amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-66-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(3-methylbutyl)-2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 498578-72-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-74-8 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-76-0 CAPLUS

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN [1,1'-Biphenyl]-2-carboxamide, N-[(6-methyl-2-pyridinyl)methyl]-2'-{{{(3R)-3-(4-nitrophenyl)-1-oxobutyl]amino}methyl}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 498578-77-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(4-fluorophenyl)-2'-[[[(4-fluorophenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-92-0 CAPLUS
CN 2-Pyrimidinepropanamide, N-[[2'-[[[(2,4-difluorophenyl)methyl]amino]carbonyl][1,1'-biphenyl]-2-yl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 498578-95-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[(4-fluorophenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 498578-96-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(6-methyl-2-pyridinyl)methyl]-2'-{{{(3R)-1-oxo-3-phenylbutyl]amino}methyl}- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 498578-98-6 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[(4-hydroxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498578-99-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-6,6'-dimethyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 498579-00-3 CAPLUS

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[3-(1-methylethoxy)propyl]- (9CI) (CA INDEX NAME)



RN 498579-01-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-cyclopentyl-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498579-07-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(1,3-dimethylbutyl)-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 498579-15-0 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-(1H-benzimidazol-2-ylmethyl)-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 498579-18-3 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]-N-[(4-(methylsulfonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)





RN 498579-43-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
GI



I

AB The voltage-gated potassium channel Kv1.5 is regarded as a promising target for the development of new atrial selective drugs with fewer side effects. In the present study, several ortho,ortho-disubstituted bisaryl compds., e.g. I [R1 = Me2CHCH2CH2, 2,4-F2C6H3CH2, 2-(2-pyridyl)ethyl, etc.; R2 = PhCH2OCO, 4-MeOC6H4CH2CO, PhCH2CH2, etc.] were synthesized and screened for their ability to block Kv1.5 channels expressed in Xenopus oocytes. The observed structure-activity relationship was described by a pharmacophore model that consists of three hydrophobic centers in a triangular arrangement. The hydrophobic centers are matched by a Ph or pyridyl ring of the bisaryl core and both ends of the side chains. The most potent compds. I [R1 = 2-(2-pyridyl)ethyl; R2 = PhCH2OCO, (S)-PhCHMeOCO] inhibited the Kv1.5 channel with sub-micromolar half-blocking concns. and displayed 3-fold selectivity over Kv1.3 and no significant effect on the HERG channel and sodium currents. In addition, compds. I [R1 = 2-(2-pyridyl)ethyl, R2 = PhCH2OCO; R1 = 2,4-F2C6H3CH2, R2 = 4-MeOC6H4CH2CO] have shown antiarrhythmic effects in a pig model.
AN 2003:49604 CAPLUS
DN 138:254915
TI Identification, Synthesis, and Activity of Novel Blockers of the Voltage-Gated Potassium Channel Kv1.5
AU Peukert, Stefan; Brendel, Joachim; Pirard, Bernard; Brueggemann, Andrea; Below, Peter; Kleemann, Heinz-Werner; Hemmerle, Horst; Schmidt, Wolfgang
CS Medicinal Chemistry and DG Cardiovascular, Aventis Pharma Deutschland GmbH, Frankfurt/Main, D-65926, Germany
SO Journal of Medicinal Chemistry (2003), 46(4), 486-498
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 138:254915
IT 498577-46-1P 498579-43-4P 502169-75-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of o-[o-(aminomethyl)phenyl]arenecarboxamides as blockers of the voltage-gated potassium channel Kv1.5 and antiarrhythmic agents)
RN 498577-46-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





RN 498579-43-4 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(3R)-1-oxo-3-phenylbutyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 502169-75-7 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(3S)-1-oxo-3-phenylbutyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 502169-74-6
CMF C31 H31 N3 O2

Absolute stereochemistry.

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
left vs. right pig atrium in comparison with IKr blockers)
RN 498577-46-1 CAPLUS
CN [1,1'-Biphenyl]-2-carboxamide, N-[(2,4-difluorophenyl)methyl]-2'-[[[(4-methoxyphenyl)acetyl]amino]methyl]- (9CI) (CA INDEX NAME)





RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
AB Inhibition of the cardiac Kv1.5 channel, the mol. base for the human cardiac ultrarapid delayed rectifier potassium current (IKur), is considered a new promising atrial selective antiarrhythmic concept since this channel is presumed to contribute to atrial but not ventricular repolarization in the human heart. In a previous study in pigs we found clear baseline differences in refractoriness between left and right atrium with shorter effective refractory periods (ERPs) of the left atrium associated with a high left atrial vulnerability for tachyarrhythmias. In this newly established model we compared atrial and ventricular effects of two novel IKur blockers, S9947 and S20951, with the IKr blockers dofetilide, azimilide, ibutilide and d,l-sotalol. In pentobarbital anesthetized pigs (n=45) we determined ERPs in the free walls of both atria with the S1-S2-stimulus method at three basic cycle lengths (BCL 240/300/400 ms) and QTc-intervals. The incidence of atrial tachyarrhythmias triggered by the S2-extrastimulus of the left atrium was evaluated (referred to as left atrial vulnerability).In contrast to IKr blockade, IKur blockade had no effect on the QT-interval, but prolonged the atrial ERP. The IKur blockers were significantly stronger on left atrial ERP, IKr blockers on right atrial ERP (P<0.05 for all compds. tested). At 240 ms BCL the IKur blocker S20951, 3 mg/kg, prolonged left vs. right atrial ERP by 28±5 ms vs. 12±3 ms and S9947, 3 mg/kg, by 45±7 ms vs. 19±6 ms. By contrast the effect of dofetilide, 10 μg/kg, was stronger on the right than left atrium (47±6 ms vs. 25±2 ms), a profile also found with azimilide (5 mg/kg, 43±3 ms vs. 17±3 ms), ibutilide (15 μg/kg, 70±10 ms vs. 29±4 ms) and d,l-sotalol (1.5 mg/kg, 57±6 ms vs. 36±4 ms). The IKur blockers, S20951and S9947, significantly decreased left atrial vulnerability (-82% and -100%, resp., P<0.01) in contrast to the selective IKr blocker dofetilide (-14; n.s.). In conclusion, IKur and IKr blockers showed substantial differences in their atrial and ventricular actions in pigs. IKr blockers were stronger on right atrial ERP, IKur blockers on left atrial ERP, suggesting interatrial differences in the expression of potassium channels. In contrast to selective IKr blockade, IKur blockade inhibited left atrial vulnerability and had no effect on the QT-interval. Thus, blockade of IKur seems to be a promising atrial selective antiarrhythmic concept.
AN 2002:787958 CAPLUS
DN 138:395757
TI Electrophysiological and antiarrhythmic effects of the novel IKur channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the IKr blockers dofetilide, azimilide, dl-sotalol and ibutilide
AU Knobloch, Karsten; Brendel, Joachim; Peukert, Stefan; Rosenstein, Bjoern; Busch, Andreas E.; Wirth, Klaus J.
CS Industriepark Hoechst, Aventis Pharma, DG Cardiovascular Diseases, Frankfurt am Main, 65926, Germany
SO Naunyn-Schmiedeberg's Archives of Pharmacology (2002), 366(5), 482-487
CODEN: NSAPCC; ISSN: 0028-1298
PB Springer-Verlag
DT Journal
LA English
IT 498577-46-1, S 20951
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(electrophysiol. and antiarrhythmic effects of IKur channel blockers on

Date not good

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
GI



I

AB Title compds. [I; R1 = CO2R9, SO2R10, COR11, CONR12R13, CSNR12R13; R9, R10, R11, R12 = CmH2mR14; m = 0-4; R14 = (F-substituted) alkyl, cycloalkyl, (substituted) Ph, naphthyl, furyl, etc.; m ≠ 0 if R14 = alkoxy, cycloalkoxy, SO2Me, OCF3; R13 = H, alkyl; R2 = H, alkyl; R3 = CnH2nR16, n = 0-4; n ≠ 0 if R16 = OR17, SO2Me; R17 = H, alkyl, cycloalkyl, CF3, (substituted) Ph, etc., R16 = (F-substituted) alkyl, cycloalkyl, (substituted) Ph, naphthyl, furyl, etc.; R4 = H, alkyl, etc.; R5, R6, R7, R8 = H, halo, CF3, NO2, cyano, etc.] were prepared Thus, 2'-aminomethylbiphenyl-2-(N-phenethyl)carboxamide (preparation given) and NaHCO3 in dioxane and H2O were treated dropwise with 4-trifluoromethylbenzyl-N-succinimide carbonate (preparation given) in dioxane followed by 12 h stirring at room temperature to give 2'-(4-trifluoromethylbenzyloxycarbonylaminomethyl)-biphenyl-2-(N-phenethyl)carboxamide. Tested I inhibited Kv1.5 potassium flow with IC50 = 0.3-6.1 μM. β-Blockers and IKs-channel blockers can be used for the tablet formulation.
AN 2001:239812 CAPLUS
DN 134:280606
TI Preparation of 2'-aminomethylbiphenyl-2-carboxamides as Kv1.5 potassium channel blockers.
IN Brendel, Joachim; Schmidt, Wolfgang; Below, Peter
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO Ger. Offen., 28 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 19947457	A1	20010405	DE 1999-19947457	19991002
CA 2385859	AA	20010412	CA 2000-2385859	20000919
WO 2001025189	A1	20010412	WO 2000-EP9151	20000919

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

	BR 2000014465	A	20020611	BR 2000-14465	20000919
	EP 1222163	A1	20020717	EP 2000-967703	20000919
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	TR 200200883	T2	20020923	TR 2002-200200883	20000919
	JP 2003511363	T2	20030325	JP 2001-528137	20000919
	EE 200200160	A	20030415	EE 2002-160	20000919
	AU 766365	B2	20031016	AU 2000-77778	20000919
	NZ 518065	A	20040827	NZ 2000-518065	20000919
	US 6531495	B1	20030311	US 2000-698078	20001030
	NO 2002001398	A	20020531	NO 2002-1398	20020320
	ZA 2002002521	A	20021030	ZA 2002-2521	20020328
	US 2003171351	A1	20030911	US 2002-252385	20020924
	US 6686395	B2	20040203		
	US 2004102513	A1	20040527	US 2003-691624	20031024
PRAI	DE 1999-19947457	A	19991002		
	WO 2000-EP9151	W	20000919		
	US 2000-675674	A2	20000929		
	US 2000-698078	A3	20001030		
	US 2002-252385	A3	20020924		

OS MARPAT 134:280606

IT **332378-64-0P 332378-68-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminomethylbiphenylcarboxamides as Kv1.5 potassium channel blockers)

RN 332378-64-0 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, N-(3-methylbutyl)-2'-[[[(1-methylethyl)sulfonyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 332378-68-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[[[(1-methylethyl)sulfonyl]amino]methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

GI



I II

AB Benzamide derivs. I (R1 = H, alkyl, etc.; R2 = H, alkyl, haloalkyl, etc.; R3, R4 = H, alkyl, etc.; R3R4 taken together form oxo; R5 = H, halo, nitro, hydroxy, etc.; R6 = H, alkyl, acyl; A = aminomethylene, alkanediyl, alkenediyl, etc.; X, Y = nitrogen, methine; n = integer) were disclosed as vasopressin antagonists. I are useful for the treatment or prevention of hypertension, heart failure renal insufficiency, edema, ascites, vasopressin parasecretion syndrome, hepatocirrhosis, hyponatremia, hypokalemia, diabetic and circulation disorders. An example compound, 1-[4-[2-(4-methylphenyl)benzoylamino]benzoyl]-5-[[(4-methyl-1-piperazinyl)carbonyl]methyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (II) was prepared in several steps.

AN 1995:807928 CAPLUS

DN 123:198646

TI Benzamide derivatives and their use as vasopressin antagonists

IN Setoi, Hiroyuki; Ohkawa, Takehiko; Zenkoh, Tatsuya; Hemmi, Keiji; Tanaka, Horokazu

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO Eur. Pat. Appl., 110 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 620216	A1	19941019	EP 1994-105344	19940407
	EP 620216	B1	20030108		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5521170	A	19960528	US 1994-220695	19940331
	AT 230729	E	20030115	AT 1994-105344	19940407
	ES 2185635	T3	20030501	ES 1994-105344	19940407
	AU 9459322	A1	19941020	AU 1994-59322	19940408
	AU 679719	B2	19970710		
	CA 2121112	AA	19941014	CA 1994-2121112	19940412
	JP 07002800	A2	19950106	JP 1994-72997	19940412
	CN 1098406	A	19950208	CN 1994-103577	19940412

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

	CN 1058710	B	20001122		
	HU 70197	A2	19950928	HU 1994-1041	19940412
	ZA 9402325	A	19950216	ZA 1994-2325	19941031
PRAI	GB 1993-7527	A	19930413		

OS MARPAT 123:198646

IT **168046-00-2P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzamide derivs. vasopressin antagonists)

RN 168046-00-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxamide, 2'-[(acetylamino)methyl]-N-[4-[(3,4-dihydro-1(2H)-quinolinyl)carbonyl]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

AB The biphenyl-containing pseudoamino acids 2'-(aminomethyl)biphenyl-2-carboxylic acid (Abc) and 2'-(aminomethyl)biphenyl-2-acetic acid (Aba) are used as rigid spacers in the backbone of the cyclic peptides cyclo(Abc-Ala-Phe-Gly)2 (5), cyclo(Abc-Ala-Val-Gly)2 (6), cyclo(Aba-Gly-Phe-Ala)2, and cyclo(Aba-Ala-Phe-Gly)2. Three different interconverting diastereomers are found in solns. of each of these cyclopeptides due to the atropisomerism of the biphenyl units. NMR techniques and mol. dynamics calcns. allow to conclude that the major diastereoisomer of 5 (and 6) in d6-DMSO adopts a β-sheet conformation. It is proposed that the pseudo-amino acid (R)-Abc forms, when attached to L-amino acids, a H-bonding pattern comparable to a β-turn.

AN 1994:605957 CAPLUS
DN 121:205957

TI Antiparallel β-sheet conformation in cyclopeptides containing a pseudo-amino acid with a biphenyl moiety

AU Brandmeier, Volker; Sauer, Wolfgang H. B.; Feigel, Martin
CS Inst. Org. Chem., Univ. Erlangen-Nuernberg, Erlangen, D-91054, Germany

SO Helvetica Chimica Acta (1994), 77(1), 70-85
CODEN: HCACAV; ISSN: 0018-019X
DT Journal
LA English

IT 158066-17-2P 158066-18-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, hydrazinolysis, deblocking, and peptide cyclization of, cyclopeptide from)

RN 158066-17-2 CAPLUS
CN Glycine, N-[N-[N-[[2'-[[[N-[N-[N-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]carbonyl]-L-alanyl]-L-phenylalanyl]glycyl]amino]methyl][1,1'-biphenyl]-2-yl]carbonyl]-L-alanyl]-L-phenylalanyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 158066-18-3 CAPLUS
CN Glycine, N-[N-[N-[[2'-[[[N-[N-[N-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl][1,1'-biphenyl]-2-yl]carbonyl]-L-alanyl]-L-valyl]glycyl]amino]methyl][1,1'-biphenyl]-2-yl]carbonyl]-L-alanyl]-L-valyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



5/04/05

=> logoff y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	54.35	215.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.30	-7.30

STN INTERNATIONAL LOGOFF AT 18:54:17 ON 04 MAY 2005